| 赵璐,宋永波,任武,等.洛铂腔内灌注治疗恶性胸腹腔积液病人的临床观察[J].安徽医药,2017,21(6):1110-1112. |
| 洛铂腔内灌注治疗恶性胸腹腔积液病人的临床观察 |
| The clinical observation of lobaplatin perfusion for the treatment of malignant pleural effusion and ascites patientsZHAO Lu,SONG Yongbo,REN Wu,ZHANG Yanling,DU Xiaoming,KONG Fengjiao (Department of Medical Oncology,General Hospital of Wanbei Coal and Electricity Group, Suzhou,Anhui 234000,China) Abstract:Objective |
| 投稿时间：2016-08-31 |
| DOI： |
| 中文关键词: 洛铂 恶性胸腹腔积液 腔内灌注化疗 |
| 英文关键词: Lobaplatin Malignant pleural effusion and ascites Intravesical instillation chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 2661 |
| 全文下载次数: 579 |
| 中文摘要: |
| 目的 探讨洛铂腔内灌注治疗恶性胸腹腔积液的近期疗效及药物毒副作用。 方法 对确诊为恶性胸腹腔积液的56例病人采用抛硬币法随机分为洛铂(LBP)组和顺铂(DDP)组,每组28例,均采用腔内灌注,比较两组间近期疗效、不良反应及生活质量改善情况。 结果 LBP组总有效率为75.0%,而DDP组总有效率为46.4%,LBP组明显高于DDP组(P<0.05)。进一步分析显示,在胸腔积液中LBP组有效率(85.7%)明显优于DDP组(50.0%)(P<0.05),在腹腔积液中有效率(64.3%)也高于DDP组(41.7%),但差异无统计学意义(P>0.05)。LBP组白细胞减少、胃肠道反应及肾功能损害的发生率明显低于DDP组,且无Ⅲ、Ⅳ级毒副反应发生(P<0.05)。LBP组与DDP组生活质量改善率分别为85.7%和60.7%,LBP组明显高于DDP组(P<0.05)。 结论 LBP腔内灌注治疗恶性胸腹腔积液近期疗效优于DDP,毒副反应较轻,值得临床推广应用。 |
| 英文摘要: |
| Objective To investigate the efficacy and side effects of intrapleural or intraperitoneal perfusion of lobaplatin for treating malignant pleural effusion or ascites. Method 56 malignant pleural and peritoneal effusion patients were randomly divided into LBP group (n=28) and DDP group (n=28).The LBP group patients were injected with lobaplatin and DDP group with cisplatin.Then thetherapeutic effect,side effects and quality of life between the two groups were observed. Results The curative effect rate of LBP group (75.0%) was higher than DDP group (46.4%),and this trend was more significant in pleural effusion patients (85.7% vs 50.0%) than in ascites (64.3% vs 41.7%).The incidence of white blood cell reduction,gastrointestinal reaction and renal function damage in LBP group was significantly lower than in DDP group,and no Ⅲ、Ⅳ degree side effect was occurred in LBP group.The life quality improvement rate of LBP group (85.7%) was significantly higher than DDP group (60.7%). Conclusion For treating malignant pleural effusion and ascites patients,lobaplatin perfusion was more valid than cisplatin,and the side effects is moderate,which is worth promoting. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
